CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
== Career == Woolley spent much of his career at the Rockefeller Institute for Medical Research in New York City. His major work focused on serotonin in brain chemistry: how substances such as LSD might affect the action of serotonin, how disorders of serotonin function might be responsible for mental disorders, and how serotonin might play a part in memory and learning. Though his career was shorter-lived than expected, subsequent work by others has developed many of Woolley's hypotheses in productive directions. One of his assistants, Robert Bruce Merrifield, won the Nobel Prize in Chemistry in 1984, for work on peptide synthesis they did together in the 1950s. In 1940 Woolley received the Eli Lilly and Company-Elanco Research Award from the American Society for Microbiology. In 1948 he received Eli Lilly Award in Biological Chemistry from the American Chemical Society. In 1952 he was elected to membership in the National Academy of Sciences. He served as president of the Institute of Nutrition in 1959. Woolley was an author on over 200 research papers and book articles in his thirty-year career. Books by Woolley included A Study of Antimetabolites (1952), and The Biochemical Bases of Psychoses (1962).
=== Ukraine === The epidemic of HIV/AIDS in Ukraine is quickly growing and was the reason for research into opioid agonist therapies (OAT) in the country as a means to curb the spread of HIV. Ukraine has the highest rate of HIV in Europe at 1.2% and most of the spread of HIV in Ukraine is primarily through people who inject drugs and secondarily through these drug users sexual partners. In 2016, opioid agonist therapies were only being given to 2.7% of the 346,000 people who inject drugs in Ukraine. OAT utilized Buprenorphine starting in 2004 and Methadone in 2008. However, due to the cost of OAT, government regulation prohibits the number of patients that can receive such therapies at a time, meaning a new patient can enter only after another has left. From 2010 to 2013 this number patients remained at a ceiling of roughly 9,000 patients throughout the country. As of 2016 OAT for these 9,000 patients is being administered only by narcologists at 174 licensed treatment centers.
At clinically studied doses in humans (up to 600 mg/day), which are much lower on a mg/kg basis than those used in the preceding animal studies, bicalutamide has only shown increases in testosterone levels and no testosterone suppression. There is some indication that the related NSAA nilutamide may also have SARM-like properties in certain tissues, as suggested by stimulation of erythropoiesis in men with prostate cancer. Additionally, hydroxyflutamide, the active metabolite of the related NSAA flutamide, has shown SARM-like activity in an androgen-responsive osteoblast cell line. Similarly, along with CPA, flutamide and hydroxyflutamide, though not bicalutamide, have been reported to act as SARMs or AR partial agonists in prostate cancer cells. Novel SARMs like enobosarm, with antiandrogenic effects in the prostate gland like bicalutamide but potent anabolic effects in muscle and bone, have also been developed. Bicalutamide has also been described as a functional "SARM" due to peripheral selectivity and inability to cross into the central nervous system and block ARs in this part of the body, resulting in antiandrogenic action in the periphery and lack of effects in the brain. However, while peripheral selectivity was initially observed in animal studies, bicalutamide did not end up showing peripheral selectivity in humans.
A definitive diagnosis is made after based on growth hormone concentrations or increased IGF-1 levels. In male dogs with no history of progestogen administration the possibility of a pituitary tumour needs to be examined via CT/MRI. In cats with difficult to manage diabetes but no other signs of hypersomatotropism, the potential for other causes of poor glycaemic control need to be considered.
Sources: en.wikipedia.org
3 Ca + N2 → Ca3N2 3 Mg + 2 NH3 → Mg3N2 + 3 H2 (at 900 °C) 3 Zn(NH2)2 → Zn3N2 + 4 NH3 Many variants on these processes are possible. The most ionic of these nitrides are those of the alkali metals and alkaline earth metals, Li3N (Na, K, Rb, and Cs do not form stable nitrides for steric reasons) and M3N2 (M = Be, Mg, Ca Sr, Ba). These can formally be thought of as salts of the N3− anion, although charge separation is not actually complete even for these highly electropositive elements. However, the alkali metal azides NaN3 and KN3, featuring the linear N−3 anion, are well-known, as are Sr(N3)2 and Ba(N3)2. Azides of the B-subgroup metals (those in groups 11 through 16) are much less ionic, have more complicated structures, and detonate readily when shocked.
It is unknown whether Fidel Castro was ever initiated as a Freemason and this subject is hotly debated among historians, but the fact remains that Logia Artemisa No. 38 (English: Artemis Lodge), today known as Logia Evolucion (English: Evolution Lodge), became a military training area and a meeting space to discuss revolutionary activities. At the Artemis Lodge, Freemasons, members of the A. J. E. F., and Fidel Castro, Pastorita Núñez and other revolutionaries planned the Attack on the Moncada Barracks in 1953. Before Fidel arrived, Ramón Pez Ferro turned off all the lights in the Temple and set up the three traditional lights of Freemasonry in the Masonic ara. The Masonic folkloric tradition of Cuba today maintains that during the height of the Cuban Revolution in 1956, when Fidel Castro and Raúl Castro landed the yacht Granma in Oriente Province, Fidel and Raúl were hidden from the government of Fulgencio Batista by a Masonic Lodge in the Sierra Maestra mountains. According to the story, it was here, in the Sierra Maestra Lodge, that Fidel Castro conceived of the 26th of July Movement. That summer, according to the Masonic tradition, Fidel and Raúl Castro were also initiated as Freemasons.
===== Senior residency (Part II) ===== Duration: Varies depending on the specialty and institution. Objective: Advanced training with increased responsibilities, including research and teaching. Assessment: Completion of a dissertation and successful performance in the Part II Fellowship Examination.
This advance enables the enantioselective construction of three-dimensional, sp³-rich molecules used in drug discovery and total synthesis. Sulfonyl hydrazides are commercially available as reagent feedstock.
==== Instant-release absorption profiles and Tmax ==== Oxycodone can be administered orally, intravenously, via intravenous, intramuscular, or subcutaneous injection. Along with rectal, sublingual, buccal or intranasal drug delivery. The bioavailability of oral administration of oxycodone averages within a range of 60 to 87%, with rectal administration yielding the same results; Intranasal administration of oxycodone has a bioavailability of ~77%, the same half life as oral oxycodone, along with faster Tmax previously reported as 47% for nasal spray administration due to the solution in the study exceeding the 0.3- to 0.4-mL nasal mucosa limit. Buccal bioavailability ~55%, Tmax ~60 min. Sublingual bioavailability 20% (non alkalized) ~55% (alkalized) Tmax ~60 minutes. After a dose of conventional (immediate-release) oral oxycodone, the onset of action is 10 to 30 minutes, and peak plasma levels of the drug are attained within roughly 30 to 60 minutes; in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. Mean serum concentration of controlled-release oxycodone peaks at 78 ng/ml at 1 hour and drops to 20 ng/ml at 8 hours and under 10 ng/ml at 12 hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual.
Sources: en.wikipedia.org
== History == The effectiveness of trilaciclib was evaluated in three randomized, double-blind, placebo-controlled studies in participants with extensive-stage small cell lung cancer. Combined, these studies randomly assigned 245 participants to receive either an intravenous infusion of trilaciclib or a placebo before chemotherapy. The studies then compared the two groups for the proportion of participants with severe neutropenia (a very low count of white blood cells called neutrophils) and the duration of severe neutropenia in the first cycle of chemotherapy. In all three studies, participants who received trilaciclib had a lower risk of having severe neutropenia compared to participants who received a placebo. Among those who had severe neutropenia, participants who received trilaciclib, on average, had it for a shorter time than participants who received a placebo. The U.S. Food and Drug Administration (FDA) granted the application for trilaciclib priority review and breakthrough therapy designations. The FDA granted the approval of Cosela to G1 Therapeutics, Inc.
The entactogen MDMA is a serotonin releasing agent and, while it also possesses other actions such as concomitant release of norepinephrine and dopamine and weak direct agonism of the serotonin 5-HT2 receptors, its serotonin release plays a key role in its unique entactogenic effects. Entactogens like MDMA should be distinguished from other drugs such as stimulants like amphetamine and psychedelics like LSD, although MDMA itself also has some characteristics of both of these types of agents. Coadministration of selective serotonin reuptake inhibitors (SSRIs), which block the serotonin transporter (SERT) and prevent MDMA from inducing serotonin release, markedly reduce the subjective effects of MDMA, demonstrating the key role of serotonin in the effects of the drug. Serotonin releasing agents like MDMA achieve much greater increases in serotonin levels than SSRIs and have far more robust of subjective effects. Besides MDMA, many other entactogens also exist and are known.
=== Migrations === White sharks go on vast migrations in response to food availability and temperature changes, as well as possibly to mate. One individual that was tagged off the South African coast swam to the southern coast of Australia and back within a year. Another white shark from South Africa was tracked swimming to Australia's northwestern coast and back, a journey of 20,000 km (12,000 mi; 11,000 nmi) in under nine months. In May 2024, a satellite tag was recovered from an Indonesian fisherman, which was determined to have come from a subadult female white shark tagged off the South African coast in May 2012, which swam to and was killed off the Indonesian coast in November 2016. In the northeastern Pacific, white sharks travel between the coastal US and Mexico and the Hawaiian Archipelago; they feed along the coast during fall and winter and farther out to sea during spring and summer. In the western North Atlantic, white sharks congregate between the Gulf of Maine and Cape Hatteras during spring and summer, and shift farther south toward Florida and into the Gulf of Mexico during the fall and winter. In fall, winter, and spring, some sharks disperse widely across the ocean, reaching as far east as the Azores.
A shipping container is a container with strength suitable to withstand shipment, storage, and handling. Shipping containers range from large reusable steel boxes used for intermodal shipments to the ubiquitous corrugated boxes. In the context of international shipping trade, "container" or "shipping container" is virtually synonymous with intermodal freight container (sometimes informally called a "sea can"), a container designed to be moved from one mode of transport to another without unloading and reloading.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.